SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

• Main Authors: Evelien G. E. Hurkmans (Author), Jan B. Koenderink (Author), Jeroen J. M. W. van den Heuvel (Author), Yvonne M. H. Versleijen-Jonkers (Author), Melissa H. S. Hillebrandt-Roeffen (Author), Johanne M. Groothuismink (Author), Hanneke I. Vos (Author), Winette T. A. van der Graaf (Author), Uta Flucke (Author), Grigor Muradjan (Author), Hendrik W. B. Schreuder (Author), Melanie M. Hagleitner (Author), Han G. Brunner (Author), Hans Gelderblom (Author), Anne-Marie (Author), Henk-Jan Guchelaar (Author), Eveline S. J. M. de Bont (Author), Daan J. Touw (Author), G. Jan Nijhoff (Author), Leontien C. M. Kremer (Author), Huib Caron (Author), Rachael Windsor (Author), Ana Patiño-García (Author), Anna González-Neira (Author), Federica Saletta (Author), Geoff McCowage (Author), Sumanth Nagabushan (Author), Daniel Catchpoole (Author), D. Maroeska W. M. te Loo (Author), Marieke J. H. Coenen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Despite (neo) adjuvant chemotherapy with cisplatin, doxorubicin and methotrexate, some patients with primary osteosarcoma progress during first-line systemic treatment and have a poor prognosis. In this study, we investigated whether patients with early disease progression (EDP), are cha...